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~ Complications of diabetes in an adolescent Cystic Fibrosis 
population 
S.H. Chotirmall, R Branagan, A.M. Lyons, Y. Alderazi, R. Mullins, T.B. Low, 
C. Thompson, N.G. McElvaney. Dept of Medicine; Beaumont Hospital, Dublin, 
Ireland 
Introduction: Cystic fibrosis related diabetes (CFRD) is increasing. We aim to 
determine HbA1C ranges and incidence of complications in CFRD pts when age/sex 
matched to non-CF diabetic ontrols. 
Methods: 11 CFRD patients (mean age 23.5 SE 1.49, 7M/4F) were age/sex matched 
to non-CF, type I diabetics (mean age 23.6 SE 1.52, 7M/4F). The HbA1C range 
(over 3 y), length from dx and all complications of DM recorded. 
Results: CFRD had comparable ranges of HbA1C than age/sex matched controls 
(range 4.8 15.1%, mean 7.90% SE 0.41, and 5.0 14.6%, mean 8.73% SE 0.41, 
respectively) [p-value 0.05]. Duration of DM differed b/w the gps; CFRD (mean 
3.56 yrs/median 3 yrs) and non-CF diabetics (mean 9.61 yrs/median 8 yrs) [p-value 
<0.05]. Both groups experienced hypo- and hyperglycemia. Only the control 
group (n 2, 18.1%) experienced microvascular complications. Neither group had 
macrovascular complications. DKAs were isolated to the control group; 45.0% 
(n 5). One CFRD had steroid induced iabetes, and one control patient developed 
autoimmune hypothyroidism. Other complications included recurrent urinary tract 
(n 3) and fungal nail infections (n 1). 
Conclusions: CFRD are similarly controlled compared to age/sex matched coun- 
terparts reflected by HbA1C levels. Poorer nutritional status in CF can explain 
differing mean HbA1C levels. Absence of microvascular complications in CFRD 
reflects later onset/shorter duration of DM. Both groups receive insulin, and the 
absence of DKAs among CFRD suggests presence of residual endogenous insulin 
secretion. Although HbA1C is regularly used to monitor glycaemic ontrol in both 
groups, it must not be used for diabetic screening. A formal OGTT carried out 
regularly (yearly after age 10) is the gold standard for a diagnosis of DM in all CF 
patients. 
7. Metabolic complications of CF 
~ Treatment with continuous subcutaneous insulin infusion (CSII) 
pump in Cystic Fibrosis during pregnancy 
R. Casciaro, A. Giannattasio, A. DeAlessandri, A. Amisano, L. Minicucci, 
R. Lorini. Cystic Fibrosis Cente~ G. Gaslini Institute, Genoa, Italy 
Use of continuous ubcutaneous insulin infusion (CSII) pump in type 1 diabetes 
mellitus (T1DM) saw a wild increase in the past years. 
Pregnancy in T1DM is an indication to use CSII, but we found only a few cases in 
literature about CSII during pregnancy in Cystic Fibrosis Related Diabetes (CFRD). 
We describe our experience. 
R.E (34yrs, G542X/G542X), onset of biochemical diabetes at 27yrs, was treated 
with glibenclamide, and at 33 yrs with: glargine 0.2 U/kg and short acting insulin 
before each meal. 
In dec 2004, at the beginning of pregnancy, the patient was in poor clinical 
conditions (BMI 18.9, FEV151%); after 6 weeks since conception she showed 
a worsening of glycaemic profiles, respiratory function (FEV1 43%), and loss 
of weight (5Kg) .  We started CSII treatment, which allowed her to follow a 
hypercaloric diet, with complete freedom in timetables of meals and in the amount 
and quality of food. Insulinic requirements at the beginning of treatment were 
1.2 U/Kg/die; it was subsequently reduced to 0.5 U/Kg/die. Insulinic dose was 
shared: 50% continuous basic infusion and remaining in pre-prandial boli. 
Glycemia was under ranges advises in literature (60 105 mg/dl at fast, 130 mg/dl 
one hour after meal, 120mg/dl two hours after meal; HblAc at 17 gestational 
weeks was 5.8% and at 32 gestational weeks was 6.37%). Moreover, ecografic 
controls howed a normal fetal growth. At delivery for planned caesarean section 
at 35 weeks, the baby's weight was 2.160 g (APGAR 9 10). She asked to protract 
CSII also after the delivery. (insulinic requirement ow is: 0.39 U/Kg/die). 
Conclusions: CSII is an useful aid in CFRD during pregnancy, because it allows to 
obtain an adequate caloric intake, avoiding a hyperglycaemia potentially injurious 
to the fetus. 
~Ora l  glucose tolerance testing in CF adults - cross-sectional and 
longitudinal comparisons 
RG. Middleton, J. Bishop. Ludwig Engel Centre for Respiratory Research, 
Department of Respiratory Medicine, Westmead Hospital, Sydney, Australia 
Impaired glucose tolerance and CF-related diabetes (CFRD) are associated with 
increasing morbidity and mortality. As the incidence increases with age, yearly oral 
glucose tolerance testing (OGTT) has been suggested. Whilst OGTT is sensitive at 
detecting impaired glucose tolerance, the clinical significance of a single abnormal 
test remains unclear. 
Aim: To perform cross-sectional nd longitudinal comparisons of the OGTT and 
glycosylated hemoglobin (HbAlc) measurements taken at annual review. 
Methods: OGTT (75g glucose) was commenced at 8 9am, with blood glucose 
levels measured at 0, 1, 2 hours, with HbAlc measured at time 0 in the majority 
of cases. All patients undergoing annual review were included, but the 5 known 
diabetics are analysed separately. 
Results: After exclusion of known diabetics, 49 subjects (mean age 27yrs) 
were screened. Overall, half had normal results. HbAlc ranged from 4.8~.1%. 
Blood glucose ranges were 3.5 6.6mM (fasting), 5.1 16.9mM (1 hr) and 3.1 
14.9 mM (2 hr). Many patients exhibited higher values at 1 hour, with 7 who had 
1 hr BSL > 11.0 mM but a normal 2 hr value (<7.8 mM); 17 patients with abnormal 
OGTT had normal HbA1 c, and 2 with abnormal HbA 1 c had normal OGTT. Repeat 
OGTT testing 1 2 years later, showed spontaneous normalisation i some subjects 
whilst others progressed to CFRD. 
Conclusion: Whilst OGTT appears more sensitive than HbAlc as a screening 
test for CFRD, some of the glucose intolerance may resolve spontaneously, so
the clinical significance remains unclear. Hyperglycemia at 1 hr, despite a normal 
2 hr value, suggests reduced first phase insulin secretion, which is currently being 
assessed. 
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~Once daily long acting insulin achieves good glycaemic control 
in Cystic Fibrosis related diabetes (CFRD) 
T. McGinnity, B. Harms, N. Trevellyan, G.J. Connett. Department of Paediatrics, 
Southampton General Hospital, UK 
Studies have demonstrated that CFRD is asssociated with deterioration i  respiratory 
and nutritional status. There is little information about optimal medical treatment. 
We studied the benefits of once daily long acting insulin (detemir, glargine) in 
achieving lucose homeostasis in CFRD. 
Methods: All patients tudied had CFRD and were receiving treatment with od 
long acting human insulin analogues 18 38 units/day for >12 months prior to 
study with doses titrated by a paediatric diabetologist according to BM monitoring. 
The clinical diagnosis of CFRD and the decision to initiate insulin was based 
on a "diabetic OGTT", raised post meal blood sugars, and symptoms of weight 
loss and/or declining lung function in all cases. Patients underwent blood glucose 
monitoring over a 3 day period using a minimed subcutaneous continuous glucose 
monitor. 
Results: Five of 6 identified patients (age; 11 18 years, M:F; 2:3) consented to 
the study protocol producing complete data. Mean duration of blood glucose levels 
within normal imits were 65%, 93%, 94% 96%, and 99%. Mean glucose levels were 
(range) 7.6 (2.2 17.2), 6.6 (3.8 13.7), 5.3 (2.2 9.0), 5.9 (3.4 12.9), 6.4 (4.1 11.8). 
Symptomatic hypoglycaemia did not occur. In 4 cases glucose time plots showed 
tight control with episodes of hyperglycaemia occuring around mid-day. In one with 
less good control, additional episodes of hyperglycaemia occurred around 08.00. 
Conclusions: These preliminary data indicate optimal blood glucose levels are 
achievable with the early use of long acting insulins for CFRD. Continuous blood 
glucose monitoring was a well tolerated and effective tool for assessing lycaemic 
control. This simple once daily regimen was well tolerated providing a safe, readily 
accepted and effective treatment option. 
